Knight Therapeutics

GUD · TSX · Canada

Public Market Listing

GUDTSX

TSX primary exchange listing

Live quotes, historical charts, and market capitalization for Knight Therapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
6Approved
0Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
dopamine precursorSmall molecule
Parkinson's Disease
fostamatinib(Tavalisse)
Approved
Spleen tyrosine kinase (Syk)Small molecule
Immune Thrombocytopenia
Approved
EGFR/HER2Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer
Approved
Mu-opioid receptor and norepinephrine transporter (NET)Small molecule
Diabetic Peripheral Neuropathic PainNeuropathic Pain
Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain
Approved
NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation
viloxazine(Qelbree)
Approved
norepinephrine transporterSmall molecule
Attention Deficit Hyperactivity Disorder

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
viloxazine · QelbreePhase 3Attention-Deficit/Hyperactivity Disorder
Est. primary completion 2026-12 · NCT02736656 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Tenapanor (Ibsrela)Phase 3Chronic Idiopathic Constipation (CIC)
Est. primary completion 2027-02-26 · NCT07382167 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Tenapanor (Ibsrela)Phase 3Irritable Bowel Syndrome With Constipation (IBS-C)
Est. primary completion 2031-07 · NCT05905926 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalTapentadolFDA updates Boxed Warning on Tapentadol (NDA200533)
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.